文献速递核素与放射性配体治疗肿瘤 PET/CT骨显像与常规 SPECT

[212Pb]Pb-AB001与[177Lu]Lu-PSMA-617在播散性前列腺癌小鼠模型中的治疗评价

Therapeutic evaluation of [212Pb]Pb-AB001 and [177Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-05-21

本研究在PC-3 PIP-luc细胞构建的心内注射播散性前列腺癌小鼠模型中,比较α发射体[212Pb]Pb-AB001(0.24‒1.0 MBq)与β发射体[177Lu]Lu-PSMA-617(22‒66 MBq)的疗效。[212Pb]Pb-AB001组中位生存期达47天,对照组25天,[177Lu]Lu-PSMA-617组27天;[212Pb]Pb-AB001组未检出骨病灶。作者认为[212Pb]Pb-AB001对微转移有显著疗效,但需进一步开展剂量学与毒性分析。

要点

  • [212Pb]Pb-AB001组中位生存期达47天,对照组25天,[177Lu]Lu-PSMA-617组27天。
  • [177Lu]Lu-PSMA-617呈活性依赖性骨转移减少,[212Pb]Pb-AB001组未检出骨病灶。
  • 作者认为[212Pb]Pb-AB001对微转移有显著疗效,但需进一步剂量学与毒性分析。

核心结论

  • [212Pb]Pb-AB001在所研究注射活度下对微转移显示显著疗效,在预防或治疗早期骨转移方面优于[177Lu]Lu-PSMA-617。
  • 作者认为这提示对mCRPC(包括有早期转移性疾病风险的患者)具有临床潜力,但需进一步开展包括剂量学和毒性分析在内的研究以确定活度水平。

研究设计与样本

  • 在PC-3 PIP-luc细胞中评估放射性配体的结合与内化。
  • 通过心内注射PC-3 PIP-luc细胞建立小鼠播散性前列腺癌模型,于细胞接种后7天开始治疗。
  • 治疗活度:[212Pb]Pb-AB001为0.24‒1.0 MBq,[177Lu]Lu-PSMA-617为22‒66 MBq。
  • 采用生物发光成像测量转移负荷,[18F]F-PSMA-1007 µPET/µCT测定PSMA靶向摄取,γ放射自显影评估[212Pb]Pb-AB001分布,X线摄影识别骨转移。

主要发现

  • 两种放射性配物体外结合相当。
  • 体内研究显示在临床相关器官中形成转移;µPET/µCT显示转移灶中[18F]F-PSMA-1007摄取增高,与生物发光成像结果一致。
  • 转移性异种移植瘤中[212Pb]Pb-AB001呈局灶性分布,提示器官内微转移分布不均。
  • [212Pb]Pb-AB001组中位生存期达47天,对照组25天,[177Lu]Lu-PSMA-617组27天。
  • [177Lu]Lu-PSMA-617观察到活性依赖性骨转移减少,而[212Pb]Pb-AB001治疗小鼠未检出骨病灶。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出需进一步开展包括剂量学和毒性分析在内的研究以确定活度水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metastatic castration-resistant prostate cancer (mCRPC) frequently leads to bone and soft tissue metastases, leading to poor prognosis. The beta-emitting radioligand [177Lu]Lu-PSMA-617 targets the prostate-specific membrane antigen (PSMA) and may be less efficient against micrometastatic disease. The alpha-emitting radioligand [212Pb]Pb-AB001 could offer enhanced treatment by delivering high energy over a short range. This study compared the efficacy of [212Pb]Pb-AB001 and [177Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer. METHODS: Binding and internalisation of radioligands were evaluated in PC-3 PIP-luc cells. A mouse model was established by intracardiac injection of these cells. Treatments with 0.24‒1.0 MBq [212Pb]Pb-AB001 or 22‒66 MBq [177Lu]Lu-PSMA-617 were initiated 7 d post-cell inoculation. Metastatic burden was measured using bioluminescence imaging, and PSMA-targeted uptake was determined with [18F]F-PSMA-1007 µPET/µCT. Gamma-autoradiography evaluated [212Pb]Pb-AB001 distribution, and bone metastases were identified by radiography. RESULTS: Both radioligands displayed comparable in vitro binding. In vivo studies revealed metastatic formation in clinically relevant organs. µPET/µCT demonstrated increased [18F]F-PSMA-1007 uptake in metastases, matching the bioluminescence imaging results. Focal [212Pb]Pb-AB001 distribution in the metastatic xenograft indicated heterogeneously distributed micrometastases in the organs. A median survival up to 47 d was achieved with [212Pb]Pb-AB001, compared to 25 d for controls and 27 d for [177Lu]Lu-PSMA-617. An activity-dependent reduction in bone metastases was observed for [177Lu]Lu-PSMA-617, while no bone lesions were detected in [212Pb]Pb-AB001-treated mice. CONCLUSION: [212Pb]Pb-AB001 showed significant efficacy against micrometastases and advantages over [177Lu]Lu-PSMA-617 in preventing or treating early bone metastases for the investigated injected activities. This implies clinical potential for treating mCRPC, including patients at risk of early metastatic disease, but further studies including dosimetry and toxicity analyses are required with regards to activity levels.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Høyvik AJK, Kvassheim M, Ma LW, et al. Therapeutic evaluation of [212Pb]Pb-AB001 and [177Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer. Eur J Nucl Med Mol Imaging. 2025. PMID: 40397137. doi:10.1007/s00259-025-07330-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。